Biography for Tracy Staton
Tracy Staton is the editor of FiercePharma. She has been a freelance writer for five years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at email@example.com or find her on LinkedIn.
Articles by Tracy Staton
Roche plans to cut 170 jobs in the U.S. and Germany.
South Africa plans to revamp its intellectual-property laws to make it more difficult for pharma companies to win protection for new versions of older drugs. The move comes soon after India's top court backed strict requirements for drug patents.
Maverick states could cost Big Pharma big money. Though many drugmakers have wrapped up marketing settlements with the federal government--and states willing to go along--they're now facing claims from state attorneys general who are bold, stubborn, ambitious, or all of the above.
No one expected Forest Laboratories to post quarterly sales growth. How could it? The company's flagship drug, Lexapro, lost patent protection just as last year's fiscal fourth quarter drew to a close. So, this time around, Forest's sales were destined to drop.
Biogen Idec's new multiple sclerosis pill made its debut to high expectations earlier this month. And so far, Tecfidera hasn't disappointed. As The Street reports, the drug has literally leapt onto the market. Its first week's worth of prescriptions surpassed 300, a rate that Novartis' first-to-market rival didn't hit until almost three months after launch.
Deal junkies, rejoice. Moody's Investors Service figures pharma M&A will pick up in 2013, after a not-so-exciting 2012. But even if the pace picks up, deal size probably won't increase much; we're looking at another year of small- to medium-sized buyouts, rather than megamergers.
AstraZeneca forged two oncology development deals on either side of the Atlantic.
Sanofi Pasteur is ready to aim its new 6-in-1 infant vaccine at rival GlaxoSmithKline. The vaccine maker won European approval for the immunization, putting Glaxo's Infanrix Hexa on notice for the first time since 2005.
Could Australia's success with HPV vaccination help boost similar efforts in the U.S.? If hard numbers on results could help, then yes. A BMJ study shows that immunizing young women against the human papillomavirus has already proven its worth.
At least one big AstraZeneca shareholder isn't concerned about CEO Pascal Soriot's pay package.